Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neurilemmoma 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Temozolomide 2Filgrastim 2Everolimus 2trifluridine tipiracil drug combination 1sargramostim 1poly ICLC 1pegfilgrastim 1pasireotide 1gadobutrol 1gadobenic acid 1dactolisib 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Vaccines 1Topotecan 1Surgical Procedures, Operative 1Radiotherapy 1O(6)-benzylguanine 1Methylphenidate 1Magnetic Resonance Spectroscopy 1Genistein 1Gadolinium DTPA 1Decitabine 1Cyclophosphamide 1Congresses as Topic 1Carmustine 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive × antineoplaston A10 × Clear all
NCT00003515 2017-09-29

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

Burzynski Research Institute

Phase 2 Terminated
1 enrolled

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡